-
51.
公开(公告)号:US09845508B2
公开(公告)日:2017-12-19
申请号:US15172045
申请日:2016-06-02
发明人: Mei Wei Chen , Cindy Collins , Matthew Lucas Eaton , Matthew G. Guenther , Nan Ke , Jeremy Lopez , Michael R. McKeown , David A. Orlando
IPC分类号: A61K31/165 , A61K31/166 , A61K31/167 , A61K31/195 , A61K31/196 , C12Q1/68 , A61K31/192
CPC分类号: C12Q1/6886 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/195 , A61K31/196 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.
-
公开(公告)号:US20170354732A1
公开(公告)日:2017-12-14
申请号:US15688053
申请日:2017-08-28
IPC分类号: A61K41/00 , A61K31/165 , A61K31/23 , A61K47/69 , A61K31/231 , A61K31/7034 , A61K9/51 , A61K9/00 , A61K9/50 , A61K31/357 , A61K47/02
CPC分类号: A61K41/00 , A61K9/0019 , A61K9/0053 , A61K9/5031 , A61K9/5094 , A61K9/5153 , A61K31/165 , A61K31/23 , A61K31/231 , A61K31/357 , A61K31/7034 , A61K41/0052 , A61K47/02 , A61K47/6941 , Y10S977/773 , Y10S977/906
摘要: A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.
-
公开(公告)号:US09839618B2
公开(公告)日:2017-12-12
申请号:US15366722
申请日:2016-12-01
发明人: Gavin P. Robertson , Raghavendra Gowda Chandagalu D. , Subbarao V. Madhunapantula , Gajanan S. Inamdar , Omer F. Kuzu
IPC分类号: A61K31/165 , A61K31/135 , A61K9/00 , A61K9/127 , A61K31/136 , A61K31/155 , A61K31/17 , A61K31/19 , A61K31/215 , A61K31/26 , A61K31/137 , A61K31/195 , A61K45/06 , C07C61/29 , C07C211/31 , C07C229/38 , C07C265/08 , C07C275/24 , C07C279/04 , C07C331/24 , C07C335/02
CPC分类号: A61K31/135 , A61K9/0019 , A61K9/1271 , A61K31/136 , A61K31/137 , A61K31/155 , A61K31/165 , A61K31/17 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/26 , A61K45/06 , C07C61/29 , C07C211/31 , C07C229/38 , C07C265/08 , C07C275/24 , C07C279/04 , C07C331/24 , C07C335/02
摘要: Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.
-
公开(公告)号:US20170348280A1
公开(公告)日:2017-12-07
申请号:US15174352
申请日:2016-06-06
IPC分类号: A61K31/375
CPC分类号: A61K31/375 , A61K31/165 , A61K31/167 , A61K31/277 , A61K31/4422 , A61K31/49 , A61K31/554 , A61K2300/00
摘要: A therapeutic use of ascorbyl palmitate, ascorbic acid and/or derivatives thereof to reverse or counter the adverse effects of channel blockers in the medical management of cardiovascular disease in a subject is presented. Effects of select Na- and Ca-channel blockers on collagen synthesis and deposition were evaluated in cultured human dermal fibroblasts and aortic smooth muscle cells by immunoassay. Ca and Na-channel blockers inhibited the synthesis of collagen type I and collagen type IV, the basic molecules of vascular wall stability. The inhibitory effects of the calcium and sodium channel blockers on collagen synthesis was reversed by introducing ascorbic acid and/or ascorbyl palmitate. It can be concluded that calcium and sodium channel blockers have a direct inhibitory effect on collagen synthesis, favoring the instability of the vascular wall and the progression of cardiovascular disease, an effect that is mitigated by treatment with, ascorbyl palmitate, ascorbic acid and or derivatives thereof.
-
公开(公告)号:US20170333371A1
公开(公告)日:2017-11-23
申请号:US15525375
申请日:2015-11-12
IPC分类号: A61K31/165 , C07D209/16 , A61K31/343 , G01N33/74 , A61K31/4045 , A61K45/06
CPC分类号: A61K31/165 , A61K31/202 , A61K31/343 , A61K31/4045 , A61K45/06 , C07D209/16 , G01N33/74 , G01N2800/285 , G01N2800/50 , G01N2800/52
摘要: Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (MS) in a subject who has MS, comprising administering a melatonin agonist to a subject.
-
公开(公告)号:US09821054B2
公开(公告)日:2017-11-21
申请号:US14004546
申请日:2012-03-09
申请人: Byram Bridle , Brian Lichty , Yonghong Wan , Jean-Simon Diallo , Chantal Lemay , John Bell
发明人: Byram Bridle , Brian Lichty , Yonghong Wan , Jean-Simon Diallo , Chantal Lemay , John Bell
IPC分类号: C12N7/00 , C12N15/86 , A61K39/29 , A61K39/00 , A61K38/12 , A61K38/15 , A61K38/16 , A61K45/06 , A61K31/165 , A61K31/167 , A61K31/18 , A61K31/19 , A61K31/192 , A61K31/4045 , A61K31/4406 , A61K31/4745 , A61K31/713 , A61K31/506 , A61K39/02 , A61K39/04 , A61K39/12 , A61K39/165 , A61K39/17 , A61K39/205 , A61K39/285 , A61K35/766
CPC分类号: A61K39/29 , A61K31/165 , A61K31/167 , A61K31/18 , A61K31/19 , A61K31/192 , A61K31/4045 , A61K31/4406 , A61K31/4745 , A61K31/506 , A61K31/713 , A61K35/766 , A61K38/12 , A61K38/15 , A61K38/164 , A61K39/0011 , A61K39/02 , A61K39/04 , A61K39/12 , A61K39/165 , A61K39/17 , A61K39/205 , A61K39/285 , A61K45/06 , A61K2039/545 , C12N2710/10343 , C12N2760/20232 , C12N2760/20243 , A61K2300/00
摘要: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
-
公开(公告)号:US09820967B2
公开(公告)日:2017-11-21
申请号:US14797951
申请日:2015-07-13
发明人: Tracy Mincer , Kristen Whalen
IPC分类号: A61K31/4015 , A61K45/06 , A61K31/165 , A61K31/7048 , A61K31/496 , A61K31/5383 , A61K31/7036 , A61K31/431 , A61K31/65 , A61K31/43 , A61K31/545 , A61K31/7052
CPC分类号: A61K31/4015 , A61K31/165 , A61K31/43 , A61K31/431 , A61K31/496 , A61K31/5383 , A61K31/545 , A61K31/65 , A61K31/7036 , A61K31/7048 , A61K31/7052 , A61K45/06 , Y02A50/473 , Y02A50/481 , A61K2300/00
摘要: One aspect of the invention provides a method of inhibiting an efflux pump in a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione, thereby inhibiting the efflux pump. Another aspect provides a method of inhibiting proliferation of a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby inhibiting the proliferation of the bacteria. Another aspect of the invention provides a method of increasing the efficacy of an antibiotic, the method comprising contacting a bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby increasing the efficacy of the antibiotic. Another aspect provides a method of inhibiting development of antibiotic resistance in a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby inhibiting development of resistance to the antibiotic. Another aspect of the invention provides a pharmaceutical composition for treating a bacterial infection comprising an effective amount of 3,4-dibromopyrrole-2,5-dione in a pharmaceutically acceptable excipient.
-
公开(公告)号:US09801814B2
公开(公告)日:2017-10-31
申请号:US13805784
申请日:2011-06-28
IPC分类号: A61K9/00 , A61K31/20 , A61K31/70 , A61K38/02 , A23L33/00 , A23L33/17 , A23L33/115 , A23L33/16 , A23L33/125 , A23L33/15 , A61K31/202 , A61K33/00 , A61J15/00
CPC分类号: A61K35/747 , A23L33/10 , A23L33/115 , A23L33/125 , A23L33/15 , A23L33/16 , A23L33/17 , A23L33/40 , A23V2002/00 , A61J15/00 , A61K9/0053 , A61K31/165 , A61K31/20 , A61K31/202 , A61K31/70 , A61K33/00 , A61K35/744 , A61K35/745 , A61K38/02 , B65B2230/02
摘要: Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional compositions may also include ethnicity-specific meals and organic ingredients and provide emotional appeal to the patient and/or the patient's caregiver. Methods of administering such nutritional compositions to patients in need of same are also provided.
-
公开(公告)号:US20170304332A1
公开(公告)日:2017-10-26
申请号:US15648250
申请日:2017-07-12
发明人: Alaric J. Dyckman , T.G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC分类号: A61K31/695 , C07F9/6553 , C07F9/655 , C07F9/6509 , C07F9/6503 , C07F9/62 , C07F9/572 , C07F9/54 , C07F9/117 , C07F9/09 , C07F7/08 , C07D333/16 , C07D319/20 , C07D311/76 , C07D311/58 , C07D309/12 , C07D309/06 , C07D305/08 , C07D277/24 , C07D241/12 , C07D241/04 , C07D239/26 , C07D231/20 , C07D231/12 , C07D217/24 , C07D215/14 , C07D215/12 , C07D213/70 , C07D213/69 , C07D213/38 , C07D213/32 , C07D209/46 , C07C323/29 , C07C323/25 , C07C321/28 , C07C321/22 , C07C321/16 , C07C317/32 , C07C317/28 , C07C275/26 , C07C271/34 , C07C251/54 , C07C251/52 , C07C251/50 , C07C251/44 , C07C251/42 , C07C251/38 , C07C235/46 , C07C233/65 , C07C233/41 , C07C219/24 , C07C217/74 , C07C217/58 , C07C217/52 , C07C215/42 , A61K31/661 , A61K31/505 , A61K31/4965 , A61K31/47 , A61K31/4409 , A61K31/4406 , A61K31/4402 , A61K31/44 , A61K31/426 , A61K31/4174 , A61K31/415 , A61K31/381 , A61K31/352 , A61K31/351 , A61K31/337 , A61K31/27 , A61K31/24 , A61K31/222 , A61K31/17 , A61K31/166 , A61K31/165 , A61K31/15 , A61K31/137 , A61K31/135 , C07C2601/04 , C07C2601/08 , C07C2603/74 , C07C2602/10 , C07C2601/02
CPC分类号: A61K31/695 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661 , C07B2200/05 , C07C215/42 , C07C217/52 , C07C217/58 , C07C217/74 , C07C219/24 , C07C233/41 , C07C233/65 , C07C235/46 , C07C251/38 , C07C251/42 , C07C251/44 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C275/26 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07C323/25 , C07C323/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/10 , C07C2603/74 , C07D209/46 , C07D213/32 , C07D213/38 , C07D213/69 , C07D213/70 , C07D215/12 , C07D215/14 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/04 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/081 , C07F9/091 , C07F9/117 , C07F9/5442 , C07F9/5728 , C07F9/62 , C07F9/65031 , C07F9/650952 , C07F9/65522 , C07F9/655345
摘要: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号:US20170304237A1
公开(公告)日:2017-10-26
申请号:US15632422
申请日:2017-06-26
发明人: Zhiyuan Zhang , Xiaodong Wang , Yaning Su , Hanying Ruan , Yan Ren
IPC分类号: A61K31/165 , C07D231/02 , C07C235/38 , A61K31/10 , C07C233/01 , A61K31/167 , C07D241/04 , C07D205/08
CPC分类号: A61K31/165 , A61K31/10 , A61K31/167 , C07C233/01 , C07C235/38 , C07D203/18 , C07D205/04 , C07D205/08 , C07D207/06 , C07D207/08 , C07D207/12 , C07D207/20 , C07D207/24 , C07D207/27 , C07D207/333 , C07D211/16 , C07D211/70 , C07D211/82 , C07D231/02 , C07D231/04 , C07D231/08 , C07D233/38 , C07D241/04 , C07D261/02 , C07D263/04 , C07D263/22 , C07D265/30 , C07D405/04 , C07D409/04 , C07D417/04
摘要: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
-
-
-
-
-
-
-
-
-